A Successful Finale: NRF2 COST Action Concludes with Landmark Meeting in Istanbul
The final Management Committee and Scientific Meeting for the COST Action (CA20121) BenBedPhar - Bench to Bedside transition for Pharmacological regulation of NRF2 in non communicable diseases – took place from October 9-10 at the vibrant Kadir Has University in Istanbul, marking a significant milestone for the consortium.
Our very own Christina, Leader of Working Group 3 (Translational Medicine), played an active role in the meeting. She presented the working group's key achievements and successfully reported the completion of its assigned deliverables. Furthermore, she shared recent findings from the lab on biomarker discovery in chronic rhinosinusitis and chaired a scientific session dedicated to the latest advancements in NRF2 research.
A major scientific highlight was the keynote lecture by Prof. Masayuki Yamamoto from Tohoku University, Japan—the pioneering discoverer of NRF2. He presented captivating insights into the role of the KEAP1-NRF2 pathway in cancer.
The event was a poignant farewell, as this was the consortium's final meeting before the Action concludes in October 2025. While this chapter is closing, the strong, collaborative network of NRF2 researchers that has been built will undoubtedly continue to thrive, with new partnerships already emerging.
In all, the meeting was not only a scientific success but also a memorable and enriching experience in the dynamic city of Istanbul, perfectly celebrating the consortium's fruitful four-year journey.
